Financial reports
10-Q
2024 Q1
Quarterly report
14 May 24
10-K
2023 FY
Annual report
28 Mar 24
10-Q
2023 Q3
Quarterly report
9 Nov 23
10-Q
2023 Q2
Quarterly report
10 Aug 23
10-Q
2023 Q1
Quarterly report
22 May 23
NT 10-Q
Notice of late quarterly filing
16 May 23
10-K
2022 FY
Annual report
30 Mar 23
10-Q
2022 Q3
Quarterly report
10 Nov 22
10-Q
2022 Q2
Quarterly report
9 Aug 22
10-Q
2022 Q1
Quarterly report
10 May 22
Current reports
8-K
Journey Medical Corporation Reports First Quarter 2024 Financial Results and Recent Corporate Highlights
13 May 24
8-K
Journey Medical Corporation Appoints Joseph Benesch as Chief Financial Officer
1 May 24
8-K
Journey Medical Corporation Reports Full-Year 2023 Financial Results and Recent Corporate Highlights
21 Mar 24
8-K
Journey Medical Corporation Secures Credit Facility with SWK Holdings for up to $20 Million
2 Jan 24
8-K
Departure of Directors or Certain Officers
8 Dec 23
8-K
Journey Medical Corporation Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights
7 Nov 23
8-K
Other Events
26 Sep 23
8-K
Other Events
19 Sep 23
8-K
Journey Medical Corporation Enters into an Exclusive License Agreement with Maruho Co., Ltd. for Qbrexza® in South Korea and Other Asian Nations
6 Sep 23
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
18 Aug 23
Registration and prospectus
S-8
Registration of securities for employees
15 Dec 23
424B3
Prospectus supplement
17 Feb 23
424B3
Prospectus supplement
17 Feb 23
S-3
Shelf registration
30 Dec 22
S-8
Registration of securities for employees
13 Jul 22
S-8
Registration of securities for employees
28 Mar 22
424B5
Prospectus supplement for primary offering
12 Nov 21
8-A12B
Registration of securities on exchange
12 Nov 21
S-1/A
IPO registration (amended)
10 Nov 21
S-1/A
IPO registration (amended)
10 Nov 21
Other
EFFECT
Notice of effectiveness
27 Jan 23
CORRESP
Correspondence with SEC
24 Jan 23
UPLOAD
Letter from SEC
5 Jan 23
SEC STAFF
SEC staff action: Order
29 Nov 21
CERT
Certification of approval for exchange listing
12 Nov 21
EFFECT
Notice of effectiveness
10 Nov 21
CORRESP
Correspondence with SEC
10 Nov 21
CORRESP
Correspondence with SEC
10 Nov 21
UPLOAD
Letter from SEC
10 Nov 21
CORRESP
Correspondence with SEC
10 Nov 21
Ownership
4
Change in insider ownership
31 May 24
3
Initial statement of insider ownership
31 May 24
4
LINDSAY A MD ROSENWALD
27 Mar 24
4
Claude Maraoui
25 Mar 24
4
Justin Adam Smith
25 Mar 24
4
LINDSAY A MD ROSENWALD
25 Mar 24
4
Joseph Benesch
23 Feb 24
4
Jeffrey Paley
8 Dec 23
4
Jeffrey Paley
29 Nov 23
4
Justin Adam Smith
17 Oct 23